Prolonged response of relapsed high grade serous ovarian carcinoma to the oral angiokinase inhibitor nintedanib in a patient with a germline BRCA1 mutation
- Resource Type
- Short Communication
- Source
- In
Gynecologic Oncology Case Reports January 2013 3:7-10 - Subject
- Language
- ISSN
- 2211-338X